REG-Shire plc: New Shire Board member

New Shire Board member

Dublin, Ireland - November 2, 2009 - The Board of Directors of Shire plc (LSE:
SHP, NASDAQ: SHPGY) announces that Mr David Stout joined the Board as a Non
Executive Director with effect from 31 October 2009.

Mr Stout has extensive pharmaceutical experience. Most recently he was
President, Pharmaceutical Operations at GSK. In this position he had
responsibility for pharmaceutical operations in the United States, Europe,
Japan and all other International Markets. Mr Stout was also responsible for
global manufacturing and global Biologics (vaccines) at GSK. Prior to that he
was President of GSK's US Pharmaceuticals Business and before that SmithKline
Beecham's North American Pharmaceuticals Business. Before joining SmithKline
Beecham, Mr Stout worked for many years at Schering- Plough.

Mr Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit, Inc.
and Airgas Inc.

Matt Emmens, Chairman of Shire commented;

"We are delighted to welcome David Stout to the Shire Board. He brings with him
extensive international experience in the pharmaceutical industry, which we
believe will be of great value to Shire as it continues its growth trajectory
and becomes a more global company."

For further information please contact:

Investor Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Relations

Eric Rojas (North America) +1 617 551 9715

Media Jessica Mann (Rest of the World) +44 1256 894 280

Matthew Cabrey (North America, Specialty +1 484 595 8248
Pharma)

Jessica Cotrone (North America, HGT) +1 617 613 4640

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical
company that focuses on meeting the needs of the specialist physician. Shire
focuses its business on attention deficit hyperactivity disorder (ADHD), human
genetic therapies (HGT) and gastrointestinal (GI) diseases as well as
opportunities in other therapeutic areas to the extent they arise through
acquisitions. Shire's in-licensing, merger and acquisition efforts are focused
on products in specialist markets with strong intellectual property protection
and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale
sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:
www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com

END